首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   24104篇
  免费   6579篇
  国内免费   87篇
耳鼻咽喉   381篇
儿科学   658篇
妇产科学   653篇
基础医学   1248篇
口腔科学   1473篇
临床医学   7095篇
内科学   5094篇
皮肤病学   641篇
神经病学   2997篇
特种医学   702篇
外科学   3012篇
综合类   104篇
一般理论   16篇
预防医学   3452篇
眼科学   430篇
药学   831篇
中国医学   13篇
肿瘤学   1970篇
  2023年   1369篇
  2022年   334篇
  2021年   799篇
  2020年   1293篇
  2019年   677篇
  2018年   1696篇
  2017年   1811篇
  2016年   1837篇
  2015年   1861篇
  2014年   2144篇
  2013年   2269篇
  2012年   1272篇
  2011年   1355篇
  2010年   1401篇
  2009年   1706篇
  2008年   1034篇
  2007年   843篇
  2006年   943篇
  2005年   720篇
  2004年   563篇
  2003年   587篇
  2002年   494篇
  2001年   354篇
  2000年   186篇
  1999年   290篇
  1998年   329篇
  1997年   321篇
  1996年   335篇
  1995年   283篇
  1994年   204篇
  1993年   179篇
  1992年   148篇
  1991年   113篇
  1990年   104篇
  1989年   123篇
  1988年   101篇
  1987年   72篇
  1986年   72篇
  1985年   59篇
  1984年   48篇
  1983年   45篇
  1982年   41篇
  1981年   39篇
  1980年   29篇
  1979年   35篇
  1978年   32篇
  1977年   24篇
  1974年   27篇
  1973年   18篇
  1971年   25篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen.  相似文献   
2.
3.
4.

Background

During coronavirus disease 2019 (COVID-19)–related operating room closures, some multidisciplinary thoracic oncology teams adopted a paradigm of stereotactic ablative radiotherapy (SABR) as a bridge to surgery, an approach called SABR-BRIDGE. This study presents the preliminary surgical and pathological results.

Methods

Eligible participants from four institutions (three in Canada and one in the United States) had early-stage presumed or biopsy-proven lung malignancy that would normally be surgically resected. SABR was delivered using standard institutional guidelines, with surgery >3 months following SABR with standardized pathologic assessment. Pathological complete response (pCR) was defined as absence of viable cancer. Major pathologic response (MPR) was defined as ≤10% viable tissue.

Results

Seventy-two patients underwent SABR. Most common SABR regimens were 34 Gy/1 (29%, n = 21), 48 Gy/3–4 (26%, n = 19), and 50/55 Gy/5 (22%, n = 16). SABR was well-tolerated, with one grade 5 toxicity (death 10 days after SABR with COVID-19) and five grade 2–3 toxicities. Following SABR, 26 patients underwent resection thus far (13 pending surgery). Median time-to-surgery was 4.5 months post-SABR (range, 2–17.5 months). Surgery was reported as being more difficult because of SABR in 38% (n = 10) of cases. Thirteen patients (50%) had pCR and 19 (73%) had MPR. Rates of pCR trended higher in patients operated on at earlier time points (75% if within 3 months, 50% if 3–6 months, and 33% if ≥6 months; p = .069). In the exploratory best-case scenario analysis, pCR rate does not exceed 82%.

Conclusions

The SABR-BRIDGE approach allowed for delivery of treatment during a period of operating room closure and was well-tolerated. Even in the best-case scenario, pCR rate does not exceed 82%.  相似文献   
5.
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号